Injectable collagenase clostridium histolyticum for Dupuytren's contracture.

Area of Science:

• Orthopedics
• Hand Surgery
• Pharmacology

Background:

• Dupuytren's disease severely impacts hand function and quality of life.
• Current standard treatment, surgery with hand therapy, carries significant risks.
• Nonsurgical collagenase clostridium histolyticum injections offer a potential alternative for contracture reduction.

Purpose of the Study:

• To evaluate the efficacy and safety of collagenase clostridium histolyticum injections for treating Dupuytren's disease contractures.
• To compare outcomes of collagenase clostridium histolyticum treatment versus placebo in a randomized, double-blind trial.

Main Methods:

• A prospective, randomized, double-blind, placebo-controlled, multicenter trial involving 308 patients.
• Patients received up to three injections of collagenase clostridium histolyticum (0.58 mg) or placebo into contracted cords.
• Joint manipulation was performed one day post-injection, with primary endpoint assessed 30 days after the final injection.

Main Results:

• Collagenase treatment resulted in a significantly higher success rate for contracture reduction (64.0% vs. 6.8%, P < 0.001).
• All 26 secondary endpoints, including improved joint range of motion, favored collagenase treatment (P < or = 0.002).
• Common adverse events included localized swelling, pain, and bruising; serious events were rare (tendon ruptures, complex regional pain syndrome).

Conclusions:

• Collagenase clostridium histolyticum is a safe and effective treatment for reducing contractures in advanced Dupuytren's disease.
• The drug significantly improves joint range of motion, offering a viable nonsurgical option.
• Further research and clinical application are supported by these findings.